Latest Headlines

Latest Headlines

Bristol-Myers, Sanofi catch a break in Plavix marketing case

Bristol-Myers Squibb and Sanofi scored a victory in a False Claims Act marketing case over its blood-thinner, Plavix, as a federal judge in New Jersey tossed out some allegations from a former Sanofi sales rep that the company made misleading statements about the med to gain more Medicare and Medicare coverage.

Sanofi strikes out in bid to escape France's $49M Plavix antitrust fine

No luck for Sanofi in turning over a Plavix antitrust fine. A Paris appeals court has upheld the €40.6 million ($49.7 million) penalty for trying to keep doctors and pharmacists from prescribing or subbing copycat versions of the former blockbuster blood thinner,  Law360  reports.

Bristol-Myers Squibb gets a boost for leukemia drug Sprycel

A labeling addition approved by the FDA Thursday for Bristol-Myers Squibb's leukemia drug Sprycel can only help to make up for the $4.5 billion in lost revenues since the blood thinner Plavix went off patent last year.

Sanofi plant in London set to close by end of month

A Sanofi plant in London that has been slated for closure has manufactured its last batch of drugs. Its equipment will be pulled out and moved to plants in Germany and Italy, and most of its 450 workers are set to lose their jobs by the end of the month.

Sanofi balks on jobs promises at R&D site in Toulouse

Sanofi can't shake the underproductive R&D site in Toulouse, France, without a fight from workers and French government officials. In the latest chapter of the ongoing feud, the Paris-based drug giant and a familiar critic in France's government show how far apart they stand on the fate of the research operation that brought the world the blood-thinner

France slaps Sanofi with $53M fine for 'disparaging' Plavix generics

The drugmaker has been fined by the French Competition Authority for "disparaging" generic copies of its now-off-patent bloodthinner, Plavix.

Sanofi sales, profits fall short, but CEO sticks to growth promises

WIth Sanofi riding the tail end of the latest earnings wave, its sales and profits shortfall feels like more of the same. It hasn't been a good quarter for Big Pharma, and Sanofi's results fall right in line with the rest. Its 5.3% sales drop was less severe than most, while its profits suffered a bit more, with a 34% decline.

New Bristol-Myers drug growth cushions plummeting Plavix sales

Bristol-Myers Squibb's first-quarter earnings dropped 44%, on a 27% decline in sales. Fortunately, the $3.83 billion revenue line was only slightly worse than analysts expected, given generic competition for blockbuster heart drugs Avapro and Plavix.

DoJ probes Sanofi disclosures on Plavix effectiveness

It's common knowledge now that the Plavix blood thinner is less effective in certain patients. But when did Sanofi know that its star drug didn't work so well in those people? Did the French drugmaker properly disclose any and all of its knowledge on the subject to FDA?

Medicines Co.'s blood thinner finally reaps positive results in third PhIII

If at first you don't succeed in Phase III, try, try again. Only enroll lots more patients and improve the trial design. That was The Medicines Company's strategy when it opted to pay for a third pivotal study of the blood thinner cangrelor.